This content is in French.
ALL: a constantly evolving battle
24 février 2025
#Leukemia #ALL #Oncology #Chemotherapy #Immunotherapy #Innovation
Acute lymphoblastic leukemia (ALL) is the most common pediatric cancer, accounting for 75% of childhood leukemias. It is characterized by excessive proliferation of immature cells in the bone marrow, preventing normal blood cell production and leading to fatigue, recurrent infections, and abnormal bleeding.
Thanks to advances in chemotherapy, targeted therapies, and immunotherapies, the prognosis for ALL has significantly improved. In high-income countries, these breakthroughs have led to survival rates exceeding 90% in children, with treatments tailored to each patient’s genetic profile and risk level. However, in low-income countries, managing ALL remains complex.
Acute lymphoblastic leukemia (ALL) is the most common pediatric cancer, accounting for 75% of childhood leukemias. It is characterized by excessive proliferation of immature cells in the bone marrow, preventing normal blood cell production and leading to fatigue, recurrent infections, and abnormal bleeding.
Thanks to advances in chemotherapy, targeted therapies, and immunotherapies, the prognosis for ALL has significantly improved. In high-income countries, these breakthroughs have led to survival rates exceeding 90% in children, with treatments tailored to each patient’s genetic profile and risk level. However, in low-income countries, managing ALL remains complex.
Sign in to read the rest
Reserved for healthcare professionals, free registration.
Scientific reference
Hayashi, H., et al. (2024). Treatment of pediatric acute lymphoblastic leukemia: a historical perspective. Cancers, 16(4), 723
View the source
